Ignyta

Go or no go? Abbvie, Roche and Kala await key decisions
EP Vantage
Fri, 07/26/19 - 11:04 am
FDA
AbbVie
upadacatinib
Roche
Ignyta
entrectinib
Kala Pharmaceuticals
KPI-121
dry eye disease
Joining AI Drug Discovery Race, Erasca Adds $22M For Cancer Work
Xconomy
Fri, 03/8/19 - 09:37 am
Erasca
Ignyta
artificial intelligence
Loxo's targeted therapy holds up to Roche challenge
Biopharma Dive
Sun, 10/21/18 - 11:36 pm
Roche
entrectinib
Loxo Oncology
Ignyta
Bayer
larotrectinib
Another Precision Step for Roche as Ignyta Drug Heads to Regulators
Xconomy
Mon, 09/24/18 - 03:32 pm
Roche
entrectinib
Ignyta
FDA
non-small cell lung cancer
3 Biotech Stocks That Soared This Week: Are They Buys?
Motley Fool
Sat, 12/23/17 - 11:39 pm
biotech
Ignyta
Roche
M&A
Molecular Templates
Biohaven Pharmaceuticals
trigriluzole
Roche Bets $1.7B More on Precision Oncology With Ignyta Deal
Xconomy
Fri, 12/22/17 - 09:51 am
Roche
Ignyta
M&A
precision medicine
oncology
Hunting an early FDA OK, Ignyta surges on promising snapshot of lung cancer data
Endpoints
Wed, 10/18/17 - 09:24 am
Ignyta
entrectinib
non-small cell lung cancer
Top-Performing Biotech and Drug Stocks During ASCO '15
TheStreet.com
Fri, 06/5/15 - 07:13 pm
ASCO
Ignyta
Immunogen
Puma Biotechnology
AbbVie
Roche
Bristol-Myers Squibb
Seattle Genetics
Juno Therapeutics
The 4 Overlooked Winners of ASCO
24/7 Wall St
Tue, 06/2/15 - 09:12 am
ASCO
Bristol-Myers Squibb
AbbVie
Aveo Pharmaceuticals
Ignyta
Ignyta Announces Interim Data from RXDX-101 Phase I Clinical Trial at 2014 ESMO Congress
Yahoo/BusinessWire
Sun, 09/28/14 - 09:43 am
Ignyta
RXDX-101
non-small cell lung cancer
Ignyta: Now Public With A Targeted Oncology Pipeline Poised For Success
Seeking Alpha
Mon, 02/24/14 - 09:19 am
Ignyta
oncology
Clovis Oncology
Ariad Pharmaceuticals
Mirati Therapeutics
Tesaro
Puma Biotechnology